LODGE GRASS, Mont. — Brothers Lonny and Teyon Fritzler walked amid the tall grass and cottonwood trees surrounding their boarded-up childhood home near the Little Bighorn River and daydreamed about ways to rebuild. The rolling prairie outside the single-story clapboard home is where Lonny learned from their grandfather how to break horses. It’s where Teyon…
You’re ready to leave the hospital, but you don’t feel able to care for yourself at home yet. Or, you’ve completed a couple of weeks in rehab. Can you handle your complicated medication regimen, along with shopping and cooking? Perhaps you fell in the shower, and now your family wants you to arrange help with…
The Trump administration has introduced three most-favored-nation (MFN) drug pricing initiatives designed to link U.S. pharmaceutical costs to prices paid in economically comparable countries. Most-favored-nation pricing requires manufacturers to provide rebates when U.S. prices exceed those in reference nations—a direct response to the persistent gap between U.S. drug prices and those in other developed economies….
Color Health is partnering with insurer Evry Health to offer its virtual cancer clinic to employer health plan members. The post Color Health Partners With Evry Health to Expand Access to Virtual Cancer Care appeared first on MedCity News.
Obesity and diabetes drug R&D partnerships struck in 2025 represented $20.2 billion in total deal value, a new record high, according to a new report from J.P. Morgan. While IPO activity and venture investment trended downward, M&A activity was significantly higher. The post J.P. Morgan Report: Obesity & Diabetes Dealmaking Set a New Record in…
OpenAI announced a new dedicated platform for health conversations. The company said the new offering is not intended for medical diagnosis or treatment — but rather to provide support for personal health navigation. The post OpenAI Launches ChatGPT Health: 5 Things to Know appeared first on MedCity News.
GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life. The post GSK Gets Closer to Bringing Patients a Functional…
The same forces now at play in medical aesthetics will soon appear in every therapeutic category where treatment overlaps with identity, from hormones to nootropics to genetic optimization. The post The GLP-1 Revolution: Medical Aesthetics And The Coming Battle For Control appeared first on MedCity News.
The weight loss market is at yet another inflection point. The euphoria of the past three years is now confronting the realities of how obesity medications will scale to address an epidemic that impacts over 1 billion people globally. The post The Weight Loss Market in 2026: 3 Questions That Will Shape the Next Decade…
[Sponsored] In a recent interview, Esperion President and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases. The post Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health appeared first on MedCity News.